Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study.

Rheumatol Ther · 2025 · PMC12450153 · PMID 40616720

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0700

boldest claim

The sentences

of borderline significanceP = 0.06so close (0.05 < p ≤ 0.1)

However, from baseline to week 16 a decrease in VAS of 21.4% (0.43 cm) was observed for patients in the IVIg group, and from baseline to week 40 for the combined cohort of patients a decrease of 22.4% (0.52 cm) was seen; both decreases were of borderline significance ( P = 0.06 and P = 0.05, respectively).

also in 389 other papers

did not reach statistical significanceP = 0.07so close (0.05 < p ≤ 0.1)

Also at week 16, there was a significant difference between the IVIg and placebo groups in the proportion of patients with arthritis ( P = 0.04) and arthralgia ( P = 0.009), and a numerical difference in the proportion of patients with fatigue, although this did not reach statistical significance ( P = 0.07).

also in 39,124 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.